"🌟 Witness the cutting-edge innovation of
@HemogenyxPharma
as they revolutionize drug development!Their groundbreaking methods and technologies are saving lives by creating new and effective medicines. Join the journey of scientific discovery and hope! 🚀
We have multiple collaboration agreements. Several of our product candidates have at least one agreement with a biopharmaceutical company...
...we have six of our product candidates in pipeline compared with two when
#HEMO
first listed.
We are pleased to announce that a patent application entitled METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS IN A PATIENT USING BI-SPECIFIC ANTIBODIES has been approved and issued by the United States Patent and Trademark Office.
We are happy to report that the 2nd process development run of HEMO-CAR-T cell manufacturing in our cGMP compliant clean rooms was successful. Our amazing team of scientists are moving toward engineering runs (PQ- process qualifications) of HEMO-CAR-T cells production.
We have made further patent applications in relation both to HEMO-CAR-T and to the CDX bi-specific antibodies, the latter being a joint application with GlobalCo.
Further information will be disclosed regarding these in due course.
#HEMO
#NewTherapies
Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement (“Agreement”) with Eli Lilly and Company (“Lilly”),
CAR-T can give long-lasting remission from blood cancers.
#HEMO
is proud to work with Dr June's Center for Cellular Immunotherapies at the University of Pennsylvania to take HEMO-CAR-T to clinical trials.
We are pleased to announce that a further patent application entitled MONOCLONAL ANTIBODIES TO HUMAN FLT3/FLK2 RECEPTOR PROTEIN has been approved and issued by the United States Patent and Trademark Office.
We have identified a target protein that can be incorporated into a single multipurpose CBR-based therapeutic capable of treating multiple viruses that belong to different viral families, instead of having to make a separate CBR construct for every virus.
We are happy to report that the 1st process development run of HEMO-CAR-T cell manufacturing in our cGMP compliant clean rooms was successful (10days). Our amazing team of scientists are moving toward engineering runs (PQ- process qualifications) of HEMO-CAR-T cells production.
We would like to thank our scientists, directors, consultants, and support staff for their hard work and dedication in the departing 2020!
We would also like to thank our followers and investors for their unwavering support of
#HemogenyxPharma
.
We are pleased to announce that we have signed a licence agreement with the global biopharmaceutical company
@LillyPad
Under this Agreement, Eli Lilly grants
#HEMO
an exclusive worldwide licence to certain intellectual property.
We are pleased to announce a further key step in the development of our CDX programme…
#HEMO
and
@SelexisSA
have signed a service agreement to develop the cell line for our CDX bispecific antibody for the treatment of acute myeloid leukemia.
We are pleased to announce significant progress in relation to moving our lead product candidate Chimeric Antigen Receptor T-cells toward clinical trials.
#HEMO
has applied for a pre-Investigational New Drug application meeting with the FDA…
We are a pre-clinical stage biopharmaceutical group developing new medicines and treatments for blood, autoimmune disease and bone marrow transplantation to a greater number of patients.
...Please visit our website to find out a little more :
The team of
@HemogenyxPharma
is making sure that their product candidate
#CAR_T
is stable, delivered to
#patients
suffering from
#AML
by a reliable partner with established logistics including real-time GPS tracking anywhere in the US. Quality System!
We announce the successful completion of our second Process Qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells. The process was carried out in the Company's current Good Manufacturing Practice compliant clean rooms.
Want to understand a little more about the significance of today’s RNS and what this really means?
What is
#HEMO
-CAR-T ?
“HEMO-CAR-T is made using
@HemogenyxPharma
proprietary humanised monoclonal antibody against a target on the surface of AML cells”
£60 Million will allow Hemogenyx Pharmaceuticals to accelerate the development and marketability of its product candidates as follows:
1. Achieve clinical proof of concept for the Company's CDX bi-specific antibody product candidate if and when needed including:
Our
#HEMO
scientists on a business trip to Maryland…
…A short break on the way back to NY. From Left to right: Senior Scientist Dr. Ronen Ben Jehuda Director of preclinical development Dr. Elina Shrestha, Senior Scientist Dr. Raymond Liang.
We are pleased to announce the successful completion of a full set of analytical tests required to verify the quality of the cells manufactured during three Process Qualification ("PQ") runs of the end-to-end process for HEMO-CAR-T production.
“This is the next incredibly important step on a direct path to clinical proof of concept for one of our leading product candidates....we believe this will have a significant and positive impact in the treatment of acute myeloid leukemia”
CEO & Co-Founder of
#HEMO
Dr
@vmsandler
In this short video listen to
#HEMO
CEO and Co-Founder
@vmsandler
comment on the development of HEMO-CAR-T which is progressing as we enter the manufacturing phase…
We are pleased to announce the commencement of a
#HEMO
strategic manufacturing partnership with WuXi ATU, a global contract testing development and manufacturing organisation.
We anticipate finalisation of the CDX antibody agreement and completion of commercial discussions with GlobalCo and for the continued development of CBR.
#HEMO
has now been able to make strong progress across its main projects…
Hemogenyx Pharmaceuticals announces the submission of an IND application seeking authorization from the FDA to begin a Phase I clinical trial of its lead product candidate HEMO-CAR-T for treating acute myeloid leukemia.
“…We are delighted to partner with
@SelexisSA
and access its proprietary protein expression tools and technologies, IP and know-how. The partnership is key to advancing our CDX programme into clinical trials…”
#HEMO
CEO and co-founder
@vmsandler
For over 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases…
Our
#HEMO
technology has the potential to enable many more patients suffering from devastating blood diseases to benefit from bone marrow transplantation.
We are pleased with the continued interest of GlobalCo in facilitating the advancement of the CDX antibody toward the clinic, having concluded the successful development phase of this product candidate, and excited about the progress in moving
#HEMO
-CAR-T toward clinical trials.
Based on an in-house test all US employees (as of today) are negative for the anti-
#SARSCoV2
#virus
#antibodies
. Social distancing and diligent use of PPE work. These allowed us to never stop advancing toward our main goal - Saving Patients Lives. We are "a life saving company"
Every step of the manufacturing of our
#HEMO
CAR-T for
#AML
must be made perfect.
A patient to be treated will have only one chance!
Our scientists and partners are determined to help the patients to survive and ultimately get cured…
“…We believe it is a ground-breaking new approach to treat emerging viral infections and to potentially become an effective new form of
#cancer
treatment…”
@vmsandler
CEO & Co-Founder of
#HEMO
AML, the most common type of acute leukemia in adults, has poor survival rates and is currently treated using chemotherapy rather than the potentially more benign and effective form of therapy being developed by
#HEMO
For more specific info click here :
U.S. Application No. 17/133,448
Title: METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC
PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES
Applicant: HEMOGENYX LLC
Inventor: Vladislav Sandler
Issued as U.S. Patent No. 11,945,866 on April 2, 2024.
The team of
@HemogenyxPharma
always remembers two numbers: 75 and 50. 75 people are diagnosed with
#AML
and 50 people die of AML each day in the US. We want to drastically reduce mortality caused by
#AML
Every day we work to save lives and improve the World.
“…The issue of this patent is of considerable significance for the Company because it protects the IP for both CDX and HEMO-CART-T product candidates…”
#HEMO
CEO & Co-Founder
@vmsandler
We are pleased to announce that we have achieved proof of concept for our Chimeric Bait Receptor platform technology.
#HEMO
has filed a seminal provisional patent application protecting its rights to the intellectual property covering CBR.
We are a pre-clinical stage biopharmaceutical group developing new medicines and treatments for blood, autoimmune disease and bone marrow transplantation to a greater number of patients.
...Please see our new presentation below for further information.
Hemogenyx Pharmaceuticals has signed a lease with The Janus Property Company for a new custom-designed and built laboratory in the Mink Building, located in the Manhattanville Factory District of New York, adjacent to Columbia University and City College.
This application follows successful work on manufacturability, quality, safety and other key parts of the development of HEMO-CAR-T. Once the proposed clinical investigation plan has been cleared to proceed by the FDA, the Company plans to initiate a Phase I clinical trial.
Our first small publication is out at ASH/Blood “FLT3-CD3 Bispecific Antibody Specifically Eliminates Normal Hematopoietic Progenitors and AML in Humanized Mouse Models” Clinical proof of concept is to follow.
“There’s an urgent clinical need for effective treatments for AML. WuXi ATU is proud to manufacture & test the lentiviral vectors that
#HEMO
requires to accelerate the beginning of its first clinical trial for this indication”
WuXi ATU CEO Dr David Chang
We are pleased to announce our participation in the
@HCWCO
Bioconnect Conference, in which
#HEMO
will be featured as a presenting company.
The conference will be held on a virtual platform from January 10-13, 2022.
Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly")
“…I am very excited to be on the West Side of Manhattan in the historic Manhattanville Factory District. We will be growing our staff and operations significantly over the next three years…”
Co-Founder and
#HEMO
CEO
@vmsandler
A very good paper that describes how
#COVID19
starts and develops and what intervention methods might be feasible "most patients develop neutralizing antibodies by week 3" If discovered, made into a drug and applied early neutralizing antibodies may help!
“While progress towards the next stage with GlobalCo on the CDX antibody is continuing, we have made significant steps in relation to HEMO-CAR-T. It’s efforts to combat viral pathogens such as COVID-19 are encouraging”
Sir Marc Feldmann,
#HEMO
Chairman
“…This agreement is key to advancing our HEMO-CAR-T programme into clinical trials and accelerating the timeline to deliver this innovative therapy to patients in need of a more benign and effective treatment for AML…”
@vmsandler
#HEMO
CEO & co-founder
We are pleased to issue an update on negotiations regarding the future development of our leading product candidate CDX bispecific antibody for the treatment of acute myeloid leukemia...
Here, our Founder and CEO
@vmsandler
catches up with
@TMSreach
Listen to Vlad expand about the very large patent application, why every year is a company making year, and the massive cost savings the custom-built laboratory will make for
#HEMO
Why
#HEMO
chose to take space at the Manhattanville Factory District campus…
"We are a small company that is growing very fast, and because we are growing fast and we're about to enter clinical trials, we need to expand”
@vmsandler
via
@NYBizJournal
Hemogenyx Pharmaceuticals has demonstrated in vivo that its proprietary Chimeric Bait Receptor ("CBR") can be delivered into the brain via programmed microglial cells for the potential treatment of brain cancers and certain neurodegenerative diseases
Chimeric Bait Receptor ("CBR") can be delivered intranasally in the form of messenger RNA ("mRNA") for the potential treatment of airborne viral infections.
We are pleased to announce the appointment of Dr Alan E. Walts, who joins the
#HEMO
team.
The renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management.
“…The successful completion of the licence agreement with
@LillyPad
represents a real milestone in the development of
#HEMO
…”
@vmsandler
CEO & Co-Founder of Hemogenyx Pharmaceuticals
Here,
@byFionaMacRae
of the
@DailyMailUK
writes an interesting article
“In trials, all signs of cancer disappeared in more than 80 per cent of patients with acute lymphoblastic leukaemia — the most common cancer in children — after receiving CAR T-cells”
All our Friends are invited to celebrate the opening of Hemogenyx Pharmaceutical’s Manhattan R&D facility on Thursday, August 11 at 14:00 ET.
Please, join us for a drink, a bite, and a good laugh!
#HEMO
is moving forward! 1361 Amsterdam Ave, Ste. 320 New York, NY 10027
Here, our CEO
@vmsandler
catches up with
@TMSreach
once again and expands on news of the recent agreement with biopharmaceutical company
@LillyPad
which granted
#HEMO
an exclusive world-wide license to an antibody that can be used to treat blood cancers.
Draw Down Under Financing Facility Agreement
The use of the Financing Facility will enable
#HEMO
to move our life-saving technologies forward rapidly, placing the Company in a highly competitive position in the treatment of cancer and viral diseases.
@HemogenyxPharma
is moving a step closer to its first clinical trials for HEMO-CAR-T for
#AML
The first trial training run of the first step of cell manufacturing - cell wash procedure in our own clean room!
We are pleased to announce the successful completion of our first Process Qualification (“PQ”) run of the end-to-end process for the manufacture of HEMO-CAR-T cells.
We believe that we can transform patients’ lives by delivering breakthrough therapies...
...We also believe that good business means healthy people and a better world. Follow us on
@YouTube
to find out a little more about what we do
@HemogenyxPharma
is moving the third step closer to its first clinical trials for HEMO-CAR-T for
#AML
. The first trial run for the third step of cell manufacturing- T cell transduction and expansion in our own clean room!
“…Our presentation at the
@HCWCO
Bioconnect Investment Conference provides
#HEMO
with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally…”
CEO & Co Founder
@vmsandler
“…The process toward our IND application remains on track and the change in the FDA's process is not expected to affect the outcome of the IND application or timetable for clinical trials…”
Dr
@vmsandler
CEO & Co-Founder of
#HEMO
Terminal cleaning of our clean rooms is in progress. This is a pre-requisite for a GMP certification necessary to manufacture our
#CART
therapy.
#HEMO
. We are moving toward the clinic!
Hemogenyx Pharmaceuticals is seeking a cell therapy manufacturing associate to support its cell therapy program towards in-human clinical studies…
…to join the
#HEMO
Team please see our website below for more details :
@HemogenyxPharma
is moving the second step closer to its first clinical trials for HEMO-CAR-T for
#AML
. The first trial run for the second step of cell manufacturing- T cell isolation in our own clean room!
We can announce that Andrew Wright, our Company's Financial Controller and Company Secretary has purchased 94,882 shares in
#HEMO
at an average price of 6.03p per share. Following this transaction, Mr Wright has a total interest in 1,626,991 Shares.
Here, our
#HEMO
CEO
@vmsandler
catches up with
@TMSreach
once again…
“We’re about making drugs to treat patients, save lives and everything else will follow…including the share price”
We have provided an outstanding return on investment to our shareholders increasing the value of
#HEMO
by more than 490% in 2020.
Given numerous reported developments, we have no doubt that the next year will be transformational for our company.